A Study to Compare Pharmacokinetic and Safety of TRS003 to China-approved Bevacizumab and US-licensed Avastin®
Condition: Healthy
Intervention: TRS003; China-approved Bevacizumab; US-licensed Avastin
Intervention description: 25mg/mL (4 mL/vial) Injection，Single dose of 3mg/kg Intravenous infusion for 90 minutes; 25mg/mL (4 mL/vial) Injection，Single dose of 3mg/kg Intravenous infusion for 90 minutes; 25mg/mL (4 mL/vial) Injection，Single dose of 3mg/kg Intravenous infusion for 90 minutes
Intervention MeSH terms: Bevacizumab
Phase: Phase 1
Study type: Interventional
Primary purpose: Other
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Masking description: double-blind
Enrollment: 114.0
Sex: Male
Minimum age: 18 Years
Maximum age: 55 Years
Healthy volunteers: Accepts Healthy Volunteers

Summary:

      This is a 12-week, randomized, double-blind, single-dose pharmacokinetic (PK) study.
      Approximately 114 healthy male participants (screening occurred within 28 days prior to
      dosing) will be randomized 1:1:1 to either TRS003, China-approved bevacizumab, and
      US-licensed Avastin® groups. Study drug will be dispensed as a single 3 mg/kg dose for
      intravenous infusion within 90 minutes. PK and immunogenicity samples will be collected and
      safety will be assessed. The primary objective of this study was to demonstrate
      pharmacokinetic similarity between TRS003, China-approved bevacizumab and US-licensed
      Avastin®, as measured by AUC0-inf in healthy male participants after a single 3 mg/kg dose.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Healthy, male participants, 18-55 years old with no significant medical history, and
             in good health as determined by detailed medical history, full physical examination,
             vital signs, 12-lead electrocardiogram (ECG), urinalysis and laboratory tests at
             screening.

          -  Body mass index of 17.5-30.5 kg/m^2 and body weight of 50-95 kg.

          -  Protocol-specified hematology, coagulation, blood chemistry and urinalysis within the
             laboratory normal range at screening, unless deemed not clinically significant by the
             Investigator.

          -  Participants must have adequate organ function according to the following laboratory
             values:

               1. Bone marrow function (absolute neutrophil count ≥1500/mm^3 and platelet count
                  ≥100,000/mm^3)

               2. Adequate liver function [alanine aminotransferase (ALT) ≤3 × upper limit normal
                  (ULN) and alkaline phosphatase ≤2 × ULN, total bilirubin ≤1.5 mg/dL]

               3. Adequate renal function creatinine clearance ≥60 mL/min based on Cockcroft-Gault
                  equation

          -  Participants must agree to use an acceptable form of birth control throughout the
             study and for at least 18 weeks after the study is over.

        Exclusion Criteria:

          -  Participants unable to give voluntary informed consent.

          -  Evidence or history of clinically significant disease, cancer other than adequately
             treated basal cell or squamous cell carcinoma of the skin.

          -  Participants on anticoagulant drugs, anemic or with known bleeding diatheses.

          -  Participants with a history of severe, uncontrolled hypertension, heart disease,
             cerebrovascular incidents, gastrointestinal bleeding, hemoptysis, frequent epistaxis
             or gingival bleeding.

          -  History clinically significant orthostatic hypotension, fainting spells, vasovagal
             syncope.

          -  Uncontrolled severe hypertension (140/90 mm Hg).

          -  Previous treatment with an anti-VEGF antibody or any other antibody or protein
             targeting the VEGF receptor.

          -  Use of any prescription, investigational drugs, herbal supplements or nonprescription
             drugs within 1 month or 5 half-lives (whichever is longer) prior to the first dose, or
             dietary supplements within 1 week prior to the first dose. If needed,
             paracetamol/acetaminophen may be used, but must be documented in the Concomitant
             medications/Significant non-drug therapies page of the case report form (CRF).

          -  Serious unhealed wound, cutaneous ulcer or bone fracture at the time of screening.

          -  Major surgery or major dental procedure or significant traumatic injury within 2
             months prior to screening, or any planned surgery or procedure within 3 months after
             investigational treatment administration. Participants must have recovered from all
             acute surgery- or trauma-related complications.

          -  Participant's medical and family history of recent or recurrent thromboembolism or
             other clotting and coagulation disorders.

          -  Donated blood over 400 mL within 3 months.

          -  History of relevant and clinically significant intra-abdominal inflammation,
             gastrointestinal perforation or gall bladder perforation.

          -  History of severe allergic or anaphylactic reaction to a therapeutic drug or severe
             seasonal allergies.

          -  Recent (within the last three [3] years) and/or recurrent history of acute or chronic
             bronchospastic disease (including asthma and chronic obstructive pulmonary disease,
             treated or not treated).

          -  A positive hepatitis B, hepatitis C or HIV tests at screening indicative of a current
             or past infection.

          -  Current use of tobacco or nicotine-containing products. Concomitant treatment was
             given only if Investigator believes strictly necessary and should be documented.

          -  Current use of any biologic drugs.